

Assessing the Public Health Impact of Prescription Drug Postmarketing Safety Labeling Changes

The Duke-Margolis Center for Health Policy • Washington, DC

February 8, 2018

Participant List

Vishal Ahuja

Assistant Professor of Information Technology and Operations Management, Southern Methodist University Cox School of Business, and Adjunct Assistant Professor of Clinical Sciences, University of Texas Southwestern Medical Center

Tom Bizzaro

Vice President, Health Policy and Industry Relations, FDB (First Databank, Inc.)

W. David Bradford

Professor and Busbee Chair in Public Policy, Department of Public Administration and Policy, University of Georgia

Becky Briesacher

Associate Professor of Pharmacy and Health Systems Sciences, Northeastern University School of Pharmacy

Eric Brodsky

Associate Director, Labeling Development Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Dan Budnitz

Director, Medication Safety Program, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention

Jessica Burnell

Research Assistant, Duke-Margolis Center for Health Policy

Tom Cantu

Senior Director, Global Labeling Governance, GlaxoSmithKline

Lauren Y. Choi

Senior Clinical Analyst, Safety Policy and Research Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Barbara Chong

Special Assistant for Labeling, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

William H. Crown

Chief Scientific Officer, OptumLabs

Gerald Dal Pan

Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Greg Daniel

Deputy Director, Duke-Margolis Center for Health Policy

Michaela Dinan

Assistant Professor of Medicine, Duke University School of Medicine

Bruce Donzanti

Sr. Grp. Director, Regulatory Affairs, Global Pharmacovigilance Innovation Policy, Genentech/Roche

Stacie B. Dusetzina

Associate Professor of Health Policy, Vanderbilt-Ingram Associate Professor of Cancer Research, Vanderbilt University Medical Center

Sara Eggers

Senior Decision Scientist, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Walid Gellad

Associate Professor of Medicine and Health Policy, University of Pittsburgh

C. Bernie Good

Senior Medical Director for the Center for Value Based Pharmacy Initiatives, UPMC Health Plan, and Professor of Medicine and Pharmacy, University of Pittsburgh

Ken Hornbuckle

Research Fellow – Pharmacoepidemiology, Global Patient Safety, Eli Lilly and Company

Mwango Kashoki

Associate Director for Safety, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Adam Kroetsch

Deputy Director, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Julie Lawrence

Program Officer, Patient Care, The Gordon and Betty Moore Foundation

Carol Linden

Director, Office of Regulatory Science and Innovation, U.S. Food and Drug Administration

Iris Masucci

Special Assistant for Labeling, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Mark McClellan

Director, Duke-Margolis Center for Health Policy

Gerald McEvoy

Assistant Vice President, AHFS Drug Information, Publications and Drug Information Systems Office, American Society of Health-System Pharmacists

Mary K. Olson

Associate Professor of Economics and Political Economy, Tulane University

Ellen Pinnow

Regulatory Science Lead, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Elizabeth Richardson

Managing Associate, Duke-Margolis Center for Health Policy

Matthew Rosenberg

Operations Research Analyst, Economics Staff, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Joseph Ross

Associate Professor of Medicine and Public Health, Yale School of Medicine

Patrick Ryan

Sr. Director and Head, Epidemiology Analytics, Janssen Research and Development, and Assistant Professor, Adjunct, Department of Biomedical Informatics, Columbia University Medical Center

Lisa Schwartz

Professor of Medicine and Community & Family Medicine, Dartmouth Geisel School of Medicine, and co-Director of the Center for Medicine and Media, The Dartmouth Institute for Health Policy and Clinical Practice

Lisa Stockbridge

Branch Chief, CBER Advertising & Promotional Labeling, U.S. Food and Drug Administration

Ann Marie Trentacosti

Medical Lead, Labeling Development Team, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jeff White

Staff Vice President, Clinical Pharmacy Services, Anthem, Inc.

Steven Woloshin

Professor of Medicine and Community & Family Medicine, Dartmouth Geisel School of Medicine, and co-Director of the Center for Medicine and Media, The Dartmouth Institute for Health Policy and Clinical Practice

Shanon Woodward

Operations Research Analyst, Office of Program and Strategic Analysis/Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Marta E. Wosinska

Chief Healthcare Economist, Office of the Inspector General, U.S. Department of Health and Human Services

Esther Zhou

Epidemiologist, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration